Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

IMPACT Therapeutics, Inc
南京英派藥業股份有限公司
(A joint stock company established in the People's Republic of China with limited liability)
(Stock Code: 7630)

VOLUNTARY ANNOUNCEMENT

ON-MARKET SHARE REPURCHASE

This announcement is made by IMPACT Therapeutics, Inc (the "**Company**") on a voluntary basis.

The board of directors of the Company (the "**Board**") wishes to announce that the Board has resolved to repurchase the H shares of the Company (the "**H Shares**") in the open market on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") from time to time for an aggregate amount of up to HK$100 million (inclusive of transaction costs such as brokerage commission and stamp duty) (the "**Share Repurchase**") pursuant to the general mandate (the "**Share Repurchase Mandate**") granted to the directors of the Company (the "**Directors**") and approved by the shareholders of the Company (the "**Shareholders**") at the annual general meeting (the "**AGM**") held on June 25, 2026. The Share Repurchase Mandate will remain in force from the date of passing of the relevant resolution at the AGM until the earliest of: (i) the conclusion of the next annual general meeting of the Company; (ii) the date by which the next annual general meeting of the Company is required to be held by the articles of association of the Company or any applicable laws of the PRC; or (iii) the date on which the authority granted under the relevant resolution is revoked or varied by a special resolution of the Shareholders in general meeting. Details of the Share Repurchase Mandate, together with the explanatory statement in connection therewith, are set out in the AGM circular of the Company dated June 3, 2026.

The Board shall conduct the Share Repurchase by exercising its powers granted to the Directors under the Share Repurchase Mandate and in compliance with the articles of association of the Company, the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"), the Codes on Takeovers and Mergers and Share Buy-backs, the applicable laws of the People's Republic of China and all applicable laws, regulations and rules to which the Company is subject. The Share Repurchase may be conducted until the expiration date of the Share Repurchase Mandate or the date on which the authority granted under the Share Repurchase Mandate is revoked or varied by a special resolution of the Shareholders in general meeting. The Company intends to finance the proposed Share Repurchase by its own financial resources (other than the proceeds raised from its global offering).

The Share Repurchase is intended to safeguard the value of the Company and the interests of the Shareholders. Having taken into account, among others, the trading performance of the H Shares, the business and financial position of the Company, its funding needs and the interests of the Shareholders as a whole, the Board considers that the Share Repurchase is necessary and reasonable. The Board believes that the Share Repurchase will demonstrate the Company's confidence in its own business outlook and prospects and would ultimately benefit the Company and create value for its Shareholders. The Company may make further repurchases of H Shares (other than the aforementioned) according to market conditions, but in any case, subject to the availability of the then applicable Share Repurchase Mandate. The Board believes that the Company's current financial resources would enable it to implement the Share Repurchase while maintaining a solid financial position.

As of the date of this announcement, the Company has not repurchased any H Shares under the Share Repurchase Mandate.

The Company will subsequently cancel and/or hold in treasury the repurchased H Shares, if any, as deemed appropriate by the Board. The proposed Share Repurchase shall not result in the number of the H Shares held by the public falling below the relevant minimum percentage prescribed by the Listing Rules.

Shareholders and potential investors should note that the implementation of the on-market Share Repurchase by the Company will be subject to market conditions and will be conducted at the absolute discretion of the Board and/or its authorized person(s). There is no assurance of the timing, quantity or price of any repurchases or whether the Company will repurchase any shares at all. Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
IMPACT Therapeutics, Inc
南京英派藥業股份有限公司
Dr. Sui Xiong CAI
Executive Director and Chief Executive Officer

Hong Kong, November 4, 2026

As at the date of this announcement, the Board comprises (i) Dr. Sui Xiong CAI, Dr. Ye Edward TIAN and Ms. Ning MA as executive Directors; (ii) Dr. Cong XU, Dr. Qiang XU and Mr. Tao LIU as non-executive Directors; and (iii) Dr. Edward Ming GUO, Mr. Chi Hung SIU and Dr. Liming SHAO as independent non-executive Directors.